{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:12:39Z","timestamp":1760094759576,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.biopha.2004.09.014","type":"journal-article","created":{"date-parts":[[2005,5,24]],"date-time":"2005-05-24T08:15:39Z","timestamp":1116922539000},"page":"312-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates"],"prefix":"10.1016","volume":"59","author":[{"given":"A.F.G.","family":"Cicero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Miconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Laghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nascetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gaddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2004.09.014_bib1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/ajcn\/71.2.472","article-title":"Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials","volume":"71","author":"Anderson","year":"2000","journal-title":"Am. J. Clin. Nutr."},{"issue":"4","key":"10.1016\/j.biopha.2004.09.014_bib2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1742-1241.2003.tb10490.x","article-title":"Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications","volume":"57","author":"Bhatnagar","year":"2003","journal-title":"Int. J. Clin. Pract."},{"issue":"5","key":"10.1016\/j.biopha.2004.09.014_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11883-002-0071-x","article-title":"New targets for medical treatment of lipid disorders","volume":"4","author":"Brousseau","year":"2002","journal-title":"Curr. Atheroscler. Re"},{"issue":"2","key":"10.1016\/j.biopha.2004.09.014_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/01.ATV.0000046230.02211.B4","article-title":"Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia","volume":"23","author":"Capell","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2004.09.014_bib5","first-page":"2123","article-title":"Effect of combination glipizide GITS\/Metformin on fibrinolytitc and metabolic parameters in poorly controlled type 2 diabetic subjects. Diab","volume":"25","author":"Cefalu","year":"2002","journal-title":"Care."},{"issue":"5","key":"10.1016\/j.biopha.2004.09.014_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00394-004-0478-y","article-title":"Effects of a new low dose soy protein\/\u03b2-sitosterol association on plasma lipid levels and oxidation","volume":"43","author":"Cicero","year":"2004","journal-title":"Eur. J. Nutr."},{"issue":"2","key":"10.1016\/j.biopha.2004.09.014_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00043798-200304000-00011","article-title":"Serum lipoprotein(a) levels in a large sample of subjects affected by familial combined hyperlipoproteinemia (FCH) and in general population","volume":"10","author":"Cicero","year":"2003","journal-title":"J. Cardiovasc. Risk"},{"key":"10.1016\/j.biopha.2004.09.014_bib8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0378-4347(93)80432-4","article-title":"Modification of a high-performance liquid chromatograophic method for assay of homocysteine in human plasma","volume":"617","author":"Cornwell","year":"2003","journal-title":"J. Chromatograph"},{"issue":"2","key":"10.1016\/j.biopha.2004.09.014_bib9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0009-9236(99)90054-1","article-title":"Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia","volume":"66","author":"de la Serna","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2004.09.014_bib10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0149-2918(03)80130-3","article-title":"The effect of l-carnitine on plasma lipoprotein (a) levels in hypercholesterolemic patients with type 2 diabetes mellitus","volume":"25","author":"Derosa","year":"2003","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2004.09.014_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.jhh.1001572","article-title":"Perindopril and candesartan comparative efficacy and safety in type 2 diabetic hypertensive patients","volume":"17","author":"Derosa","year":"2003","journal-title":"J. Hum. Hyper."},{"issue":"2","key":"10.1016\/j.biopha.2004.09.014_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00002018-200326020-00002","article-title":"Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management","volume":"26","author":"Dierkes","year":"2003","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.biopha.2004.09.014_bib13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00041433-200212000-00003","article-title":"HDL and triglyceride as therapeutic targets","volume":"13","author":"Fruchart","year":"2002","journal-title":"Curr. Opin. Lipidol."},{"issue":"2","key":"10.1016\/j.biopha.2004.09.014_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.ejcn.1601123","article-title":"The realisation of a project aimed at reducing the plasmatic lipid level in a large Italian rural population improves the mean calcium daily intake: the Brisighella Study","volume":"55","author":"Gaddi","year":"2001","journal-title":"Eur. J. Clin. Nutr"},{"key":"10.1016\/j.biopha.2004.09.014_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0021-9150(84)90009-1","article-title":"Controlled evaluation of panthetine, a natural hypolipemic compound, in patients with hyperlipidaemia","volume":"50","author":"Gaddi","year":"1984","journal-title":"Atherosclerosis"},{"issue":"16","key":"10.1016\/j.biopha.2004.09.014_bib16","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1161\/01.CIR.0000035280.64322.31","article-title":"New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism","volume":"106","author":"Ginsberg","year":"2002","journal-title":"Circ."},{"issue":"11","key":"10.1016\/j.biopha.2004.09.014_bib17","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/sj.ejcn.1601464","article-title":"Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes","volume":"256","author":"Hodgson","year":"2002","journal-title":"Eur. J. Clin. Nutr."},{"issue":"6","key":"10.1016\/j.biopha.2004.09.014_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11886-002-0112-7","article-title":"Hypertriglyceridemia and risk of coronary heart disease","volume":"4","author":"Hokanson","year":"2002","journal-title":"Curr. Cardiol. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2004.09.014_bib19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"issue":"18","key":"10.1016\/j.biopha.2004.09.014_bib20","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1161\/01.CIR.102.18.2284","article-title":"AHA revision 2000. A statement for healthcare professionals from the Nutrition Committee of the American Heart Association","volume":"102","author":"Kraus","year":"2000","journal-title":"Circ."},{"key":"10.1016\/j.biopha.2004.09.014_bib21","series-title":"Biomedical and Clinical Aspects of Coenzyme Q","first-page":"11","article-title":"Coenzyme Q saturation kinetics of mitochondrial enzymes: Theory, experimental aspects and biomedical implications","author":"Lenaz","year":"1991"},{"key":"10.1016\/j.biopha.2004.09.014_bib22","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1055\/s-0038-1661314","article-title":"Bioimmunoassay (BIA) of tissue plasminogen activator (t-PA) and its specific inhibitor (t-PA\/INH)","volume":"53","author":"Mahmoud","year":"1985","journal-title":"Thromb. Haemost."},{"issue":"2\u20134","key":"10.1016\/j.biopha.2004.09.014_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/biof.5520090225","article-title":"Coenzyme Q10 treatment in serious heart failure","volume":"9","author":"Munkholm","year":"1999","journal-title":"Biofactors"},{"issue":"12","key":"10.1016\/j.biopha.2004.09.014_bib24","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0149-2918(02)80095-9","article-title":"Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation","volume":"24","author":"Najib","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2004.09.014_bib25","series-title":"Biostatistics. The bare essential, 2nd ed","first-page":"139","author":"Norman","year":"2000"},{"issue":"12","key":"10.1016\/j.biopha.2004.09.014_bib26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.5414\/CPP39551","article-title":"Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia","volume":"39","author":"Okopien","year":"2001","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2004.09.014_bib27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00045415-200205000-00005","article-title":"Hypertriglyceridemia: a review beyond low-density lipoprotein","volume":"10","author":"Rapp","year":"2002","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.biopha.2004.09.014_bib28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/clinchem\/46.4.461","article-title":"Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications","volume":"46","author":"Roberts","year":"2000","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2004.09.014_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0167-5273(98)00323-4","article-title":"Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role","volume":"68","author":"Singh","year":"1999","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.biopha.2004.09.014_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.jhh.1000778","article-title":"Effect of hydrosoluble coenzyme Q10 on blood pressure and insulin resistance in hypertensive patients with coronary artery disease","volume":"13","author":"Singh","year":"1999","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.biopha.2004.09.014_bib31","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/28.6.1379","article-title":"Dextran sulfate\u2013Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol","volume":"28","author":"Warnick","year":"1982","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2004.09.014_bib32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s00125-001-0760-y","article-title":"Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus","volume":"45","author":"Watts","year":"2002","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.biopha.2004.09.014_bib33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00004836-200301000-00016","article-title":"Issues in hyperlipidemic pancreatitis","volume":"36","author":"Yadav","year":"2003","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.biopha.2004.09.014_bib34","series-title":"Coenzyme Q. Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone","first-page":"479","article-title":"A survey of the therapeutic uses of coenzyme Q. G","author":"Yamamura","year":"1985"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332205000910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332205000910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:36:13Z","timestamp":1760092573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332205000910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0753332205000910"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2004.09.014","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2005,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2004.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}